Table 7. Multivariate analysis of prognostic factors associated with PFS in sensitive and refractory patients.
| Variables | Sensitive LS-SCLC | Refractory LS-SCLC | ||||
|---|---|---|---|---|---|---|
| PFS | HR (95% CI) | p | PFS | HR (95% CI) | p | |
| Numbers of cycle | ||||||
| N ≥ 4 | 14.0 | 0.329 0.119–0.906 | 0.031 | 10.4 | 0.289 0.117–0.716 | < 0.001 |
| N < 4 | 8.3 | Ref. | 5.9 | Ref. | ||
| Treatment Modality | ||||||
| Chemoradiotherapy | 14.6 | 0.283 0.106–0.755 | 0.012 | 9.1 | 0.316 0.102–0.960 | 0.042 |
| Chemotherapy | 7.8 | Ref. | 6.2 | Ref. | ||
| LDH | ||||||
| Elevated (> 240 U/l) | 8.5 | 2.331 1.211–4.486 | 0.001 | 7.0 | 1.366 0.678–2.753 | 0.382 |
| Normal (≤ 240 U/l) | 15.3 | Ref. | 9.0 | Ref. | ||
| NLR | ||||||
| Elevated (≥ 4) | 9.2 | 1.748 1.110–2.753 | 0.016 | 6.7 | 1.283 1.088–1.546 | 0.037 |
| Normal (< 4) | 15.4 | Ref. | 9.4 | Ref. | ||
| NSE | ||||||
| Elevated (> 18 ng/ml) | 10.2 | 1.513 1.292–1.902 | 0.020 | 6.0 | 1.723 1.278–2.127 | < 0.001 |
| Normal (≤ 18 ng/ml) | 16.0 | Ref. | 10.0 | Ref. | ||
| Response | ||||||
| CR + PR | 15.0 | 0.266 0.116–0.614 | 0.002 | 9.3 | 0.342 0.163–0.718 | 0.006 |
| SD + PD | 8.7 | Ref. | 6.0 | Ref. | ||
Abbreviations: LS-SCLC: limited-stage small cell lung cancer; PFS: progression-free time; HR: hazard ratio; CI: confidence interval; LDH: lactate dehydrogenase; NLR: neutrophil-to-lymphocyte ratio; NSE: neuro-specific enolase; CR: complete response; PR: partial response; SD: disease stable; PD: disease progression.